HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients - PubMed (original) (raw)
Clinical Trial
. 2002 Feb 15;16(3):387-96.
doi: 10.1097/00002030-200202150-00010.
Mounir Ait-Khaled, Deborah A Thomas, Carol L Brosgart, Joseph J Eron Jr, Judith Feinberg, Timothy P Flanigan, Scott M Hammer, Peter W Kraus, Robert Murphy, Ramon Torres, Henry Masur; CNA2007 Study Team
Affiliations
- PMID: 11834950
- DOI: 10.1097/00002030-200202150-00010
Clinical Trial
HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients
Judith Falloon et al. AIDS. 2002.
Abstract
Objective: To assess the safety and efficacy of three new drugs in patients with antiretroviral failure and to correlate retrospectively baseline factors with virological response.
Design and setting: Open-label, 48-week, single-arm, multi-center phase II trial conducted at nine US university or government clinics and private practices.
Patients and interventions: Patients with HIV-1 RNA > or =500 copies/ml despite > or =20 weeks of treatment with at least one protease inhibitor received abacavir 300 mg twice a day, amprenavir 1200 mg twice a day and efavirenz 600 mg once a day. Other antiretrovirals were prohibited until week 16 except for substitutions for possible abacavir hypersensitivity.
Main outcome measures: HIV RNA at weeks 16 and 48.
Results: A total of 101 highly treatment-experienced patients enrolled; 60 were naive to non-nucleoside analog reverse transcriptase inhibitors (NNRTI). HIV RNA < 400 copies/ml was attained in 25 out of 101 (25%) patients at 16 weeks (35% of NNRTI-naive and 10% of -experienced patients) and 23 (23%) patients at 48 weeks (33% of naive and 7% of experienced patients). CD4 cells increased by a median of 15 x 10(6) and 43 x 10(6) cells/l at weeks 16 and 48, respectively. Drug-related rash occurred in 50 out of 99 (51%) of patients, and 17 out of 99 (17%) permanently discontinued one or more drugs as a result. Lower baseline viral load, fewer NNRTI-related mutations, absence of decreased abacavir (> or =4-fold) and efavirenz (> or =10-fold) susceptibility, and greater number of drugs to which virus was susceptible were associated with virological response at week 16.
Conclusions: Abacavir, amprenavir and efavirenz durably reduced HIV RNA and increased CD4 cell counts in a subset of treatment-experienced adults. Baseline viral load and some genotypic and phenotypic markers of resistance correlated with HIV RNA response.
Similar articles
- HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Ait-Khaled M, Rakik A, Griffin P, Stone C, Richards N, Thomas D, Falloon J, Tisdale M; CNA2007 International Study Team. Ait-Khaled M, et al. Antivir Ther. 2003 Apr;8(2):111-20. Antivir Ther. 2003. PMID: 12741623 Clinical Trial. - A controlled Phase II trial assessing three doses of enfuvirtide (T-20) in combination with abacavir, amprenavir, ritonavir and efavirenz in non-nucleoside reverse transcriptase inhibitor-naive HIV-infected adults.
Lalezari JP, DeJesus E, Northfelt DW, Richmond G, Wolfe P, Haubrich R, Henry D, Powderly W, Becker S, Thompson M, Valentine F, Wright D, Carlson M, Riddler S, Haas FF, DeMasi R, Sista PR, Salgo M, Delehanty J. Lalezari JP, et al. Antivir Ther. 2003 Aug;8(4):279-87. Antivir Ther. 2003. PMID: 14518696 Clinical Trial. - Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM, Vaida F, Bennett KK, Holohan MK, Sheiner L, Eron JJ, Wheat LJ, Mitsuyasu RT, Gulick RM, Valentine FT, Aberg JA, Rogers MD, Karol CN, Saah AJ, Lewis RH, Bessen LJ, Brosgart C, DeGruttola V, Mellors JW; AIDS Clinical Trials Group 398 Study Team. Hammer SM, et al. JAMA. 2002 Jul 10;288(2):169-80. doi: 10.1001/jama.288.2.169. JAMA. 2002. PMID: 12095381 Clinical Trial. - Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
de Truchis P, Force G, Welker Y, Mechali D, Pulik M, Chemlal K, Rouveix E, Devidas A, Praindhui D, Mamet JP; CNAF3008 Group. de Truchis P, et al. J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):178-82. doi: 10.1097/00126334-200210010-00008. J Acquir Immune Defic Syndr. 2002. PMID: 12394796 Clinical Trial. - [Pharmacological study and clinical effect of HIV protease inhibitor amprenavir].
Ishizawa M, Komatsu H. Ishizawa M, et al. Nihon Yakurigaku Zasshi. 2001 Jan;117(1):59-64. doi: 10.1254/fpj.117.59. Nihon Yakurigaku Zasshi. 2001. PMID: 11233298 Review. Japanese.
Cited by
- Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.
Pfister M, Labbé L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB; Adult AIDS Clinical Trial Group Study 398. Pfister M, et al. Antimicrob Agents Chemother. 2003 Jan;47(1):130-7. doi: 10.1128/AAC.47.1.130-137.2003. Antimicrob Agents Chemother. 2003. PMID: 12499180 Free PMC article. Clinical Trial. - Application and impact of population pharmacokinetics in the assessment of antiretroviral pharmacotherapy.
Barrett JS, Labbé L, Pfister M. Barrett JS, et al. Clin Pharmacokinet. 2005;44(6):591-625. doi: 10.2165/00003088-200544060-00003. Clin Pharmacokinet. 2005. PMID: 15910009 Review. - Burden of nonnucleoside reverse transcriptase inhibitor resistance in HIV-1-infected patients: a systematic review and meta-analysis.
Snedecor SJ, Sudharshan L, Nedrow K, Bhanegaonkar A, Simpson KN, Haider S, Chambers R, Craig C, Stephens J. Snedecor SJ, et al. AIDS Res Hum Retroviruses. 2014 Aug;30(8):753-68. doi: 10.1089/AID.2013.0262. Epub 2014 Jul 8. AIDS Res Hum Retroviruses. 2014. PMID: 24925216 Free PMC article. Review. - Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.
Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP. Maguire MF, et al. J Virol. 2002 Aug;76(15):7398-406. doi: 10.1128/jvi.76.15.7398-7406.2002. J Virol. 2002. PMID: 12097552 Free PMC article. - Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile.
Arvieux C, Tribut O. Arvieux C, et al. Drugs. 2005;65(5):633-59. doi: 10.2165/00003495-200565050-00005. Drugs. 2005. PMID: 15748098 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials